238 related articles for article (PubMed ID: 32173379)
1. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.
Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX
Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
[TBL] [Abstract][Full Text] [Related]
3. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.
Wang YX; Mao XF; Li TF; Gong N; Zhang MZ
Sci Rep; 2017 Feb; 7():43137. PubMed ID: 28230181
[TBL] [Abstract][Full Text] [Related]
4. Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.
Wu LX; Dong YP; Zhu QM; Zhang B; Ai BL; Yan T; Zhang GH; Sun L
BMC Cancer; 2021 Oct; 21(1):1128. PubMed ID: 34670518
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular targets of dezocine and their clinical implications.
Liu R; Huang XP; Yeliseev A; Xi J; Roth BL
Anesthesiology; 2014 Mar; 120(3):714-23. PubMed ID: 24263237
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like effects of dezocine in mice: involvement of 5-HT1A and κ opioid receptors.
Shang L; Duan C; Chang S; Chang N; Jia S
Behav Pharmacol; 2021 Sep; 32(6):472-478. PubMed ID: 34101632
[TBL] [Abstract][Full Text] [Related]
7. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
8. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.
Wang YH; Chai JR; Xu XJ; Ye RF; Zan GY; Liu GY; Long JD; Ma Y; Huang X; Xiao ZC; Dong H; Wang YJ
Sci Rep; 2018 Sep; 8(1):14087. PubMed ID: 30237513
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
11. Dezocine as a potent analgesic: overview of its pharmacological characterization.
Ye RR; Jiang S; Xu X; Lu Y; Wang YJ; Liu JG
Acta Pharmacol Sin; 2022 Jul; 43(7):1646-1657. PubMed ID: 34737418
[TBL] [Abstract][Full Text] [Related]
12. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
13. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
[TBL] [Abstract][Full Text] [Related]
14. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
Bee LA; Bannister K; Rahman W; Dickenson AH
Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
Picker MJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
[TBL] [Abstract][Full Text] [Related]
16. Electroacupuncture Enhances the Antiallodynic and Antihyperalgesic Effects of Milnacipran in Neuropathic Rats.
Li C; Ji BU; Kim Y; Lee JE; Kim NK; Kim ST; Koo S
Anesth Analg; 2016 May; 122(5):1654-62. PubMed ID: 26962713
[TBL] [Abstract][Full Text] [Related]
17. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
18. Dezocine attenuates the remifentanil-induced postoperative hyperalgesia by inhibition of phosphorylation of CaMKⅡα.
Zhou J; Qi F; Hu Z; Zhang L; Li Z; Wang ZJ; Tang H; Chen Z
Eur J Pharmacol; 2020 Feb; 869():172882. PubMed ID: 31863769
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring μ-opioid receptor in spinal cord.
Hou X; Weng Y; Ouyang B; Ding Z; Song Z; Zou W; Huang C; Guo Q
Brain Res; 2017 Aug; 1669():97-105. PubMed ID: 28559159
[TBL] [Abstract][Full Text] [Related]
20. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
Gonçalves L; Friend LV; Dickenson AH
Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
